{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:51:05Z","timestamp":1792813865565,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12149-025-02093-w","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:26:34Z","timestamp":1755275194000},"page":"1053-1073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the diagnostic utility of [\u2076\u2078Ga]Ga-Pentixafor in solid tumors: a systematic review"],"prefix":"10.1007","volume":"39","author":[{"given":"Saad","family":"Ruzzeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Saad","family":"Abdlkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Al-Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egesta","family":"Lopci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Moghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"2093_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40495-015-0044-8","volume":"2","author":"Y Wang","year":"2016","unstructured":"Wang Y, Xie Y, Oupick\u00fd D. Potential of CXCR4\/CXCL12 chemokine axis in cancer drug delivery. Curr Pharmacol Rep. 2016;2(1):1\u201310.","journal-title":"Curr Pharmacol Rep"},{"issue":"11","key":"2093_CR2","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","volume":"8","author":"Y Shi","year":"2020","unstructured":"Shi Y, Riese DJ, Shen J. The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;8(11):574667.","journal-title":"Front Pharmacol"},{"key":"2093_CR3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263693","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, et al. Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using68 Ga-PentixaFor PET. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.121.263693.","journal-title":"J Nucl Med"},{"issue":"3","key":"2093_CR4","first-page":"410","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med Off Publ Soc Nucl Med. 2015;56(3):410\u20136.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"15","key":"2093_CR5","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.3390\/cancers14153814","volume":"14","author":"D Albano","year":"2022","unstructured":"Albano D, Dondi F, Bertagna F, Treglia G. The role of [68Ga]Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma: a systematic review. Cancers. 2022;14(15):3814.","journal-title":"Cancers"},{"issue":"10","key":"2093_CR6","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.3390\/jcm13102945","volume":"13","author":"M Zamanian","year":"2024","unstructured":"Zamanian M, Albano D, Treglia G, Rizzo A, Abedi I. The clinical role of CXCR4-Targeted PET on lymphoproliferative disorders: a systematic review. J Clin Med. 2024;13(10):2945.","journal-title":"J Clin Med"},{"issue":"6","key":"2093_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fmed.2019.00069","volume":"9","author":"B Jamet","year":"2019","unstructured":"Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, et al. Interest of pet imaging in multiple myeloma. Front Med. 2019;9(6):69.","journal-title":"Front Med"},{"issue":"9","key":"2093_CR8","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/diagnostics12092135","volume":"12","author":"B Hadebe","year":"2022","unstructured":"Hadebe B, Sathekge MM, Aldous C, Vorster M. Current status of 68Ga-Pentixafor in solid tumours. Diagnostics. 2022;12(9):2135.","journal-title":"Diagnostics"},{"issue":"1","key":"2093_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13550-021-00822-6","volume":"11","author":"R Lewis","year":"2021","unstructured":"Lewis R, Habringer S, Kircher M, Hefter M, Peuker CA, Werner R, et al. Investigation of spleen CXCR4 expression by [68Ga]Ga-Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res. 2021;11(1):77.","journal-title":"EJNMMI Res"},{"key":"2093_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2022.847810","author":"O Mbakaza","year":"2022","unstructured":"Mbakaza O, Vangu MDTW. 18F-FDG PET\/CT imaging: normal variants, pitfalls, and artifacts musculoskeletal, infection, and inflammation. Front Nucl Med. 2022. https:\/\/doi.org\/10.3389\/fnume.2022.847810.","journal-title":"Front Nucl Med"},{"issue":"1","key":"2093_CR11","first-page":"293","volume":"36","author":"RR Flavell","year":"2016","unstructured":"Flavell RR, Naeger DM, Aparici CM, Hawkins RA, Pampaloni MH, Behr SC. Malignancies with low fluorodeoxyglucose uptake at PET\/CT: pitfalls and prognostic importance: resident and fellow education feature. Radiogr Rev Publ Radiol Soc Am Inc. 2016;36(1):293\u20134.","journal-title":"Radiogr Rev Publ Radiol Soc Am Inc"},{"issue":"3","key":"2093_CR12","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21(3):e146\u201356.","journal-title":"Lancet Oncol"},{"key":"2093_CR13","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;372. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71 Accessed 01 oct 2024","DOI":"10.1136\/bmj.n71"},{"key":"2093_CR14","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2093_CR15","doi-asserted-by":"publisher","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529\u201336. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","DOI":"10.7326\/0003-4819-155-8-201110180-00009"},{"key":"2093_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"issue":"8","key":"2093_CR17","doi-asserted-by":"publisher","first-page":"9288","DOI":"10.18632\/oncotarget.7063","volume":"7","author":"C Lapa","year":"2016","unstructured":"Lapa C, L\u00fcckerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A, et al. [68Ga]Ga-Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in small cell lung cancer\u2014initial experience. Oncotarget. 2016;7(8):9288\u201395.","journal-title":"Oncotarget"},{"issue":"3","key":"2093_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.7150\/thno.13986","volume":"6","author":"C Lapa","year":"2016","unstructured":"Lapa C, L\u00fcckerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, et al. 68 Ga-Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in glioblastoma. Theranostics. 2016;6(3):428\u201334.","journal-title":"Theranostics"},{"issue":"5","key":"2093_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2967\/jnumed.115.161034","volume":"57","author":"T Vag","year":"2016","unstructured":"Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, et al. First experience with chemokine receptor CXCR4\u2013Targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57(5):741\u20136.","journal-title":"J Nucl Med"},{"issue":"57","key":"2093_CR20","doi-asserted-by":"publisher","first-page":"96732","DOI":"10.18632\/oncotarget.18235","volume":"8","author":"C Lapa","year":"2017","unstructured":"Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T, et al. Targeting CXCR4 with [68Ga]Ga-Pentixafor: a suitable theranostic approach in pleural mesothelioma? Oncotarget. 2017;8(57):96732\u20137.","journal-title":"Oncotarget"},{"issue":"1","key":"2093_CR21","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/RLU.0000000000001435","volume":"42","author":"C Bluemel","year":"2017","unstructured":"Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, et al. Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients. Clin Nucl Med. 2017;42(1):e29-34.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2093_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.7150\/thno.18754","volume":"7","author":"RA Werner","year":"2017","unstructured":"Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach. Theranostics. 2017;7(6):1489\u201398.","journal-title":"Theranostics"},{"issue":"1","key":"2093_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","volume":"8","author":"T Vag","year":"2018","unstructured":"Vag T, Steiger K, Rossmann A, Keller U, Noske A, Herhaus P, et al. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. EJNMMI Res. 2018;8(1):90.","journal-title":"EJNMMI Res"},{"issue":"9","key":"2093_CR24","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fonc.2019.00770","volume":"14","author":"RA Werner","year":"2019","unstructured":"Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, et al. CXCR4-directed imaging in solid tumors. Front Oncol. 2019;14(9):770.","journal-title":"Front Oncol"},{"issue":"9","key":"2093_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3389\/fonc.2019.00503","volume":"12","author":"M Breun","year":"2019","unstructured":"Breun M, Monoranu CM, Kessler AF, Matthies C, L\u00f6hr M, Hagemann C, et al. [68Ga]-Pentixafor PET\/CT for CXCR4-mediated imaging of vestibular schwannomas. Front Oncol. 2019;12(9):503.","journal-title":"Front Oncol"},{"issue":"1","key":"2093_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40644-021-00391-w","volume":"21","author":"P Linde","year":"2021","unstructured":"Linde P, Baues C, Wegen S, Trommer M, Quaas A, Rosenbrock J, et al. Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in esophageal cancer\u2014a first clinical approach. Cancer Imaging. 2021;21(1):22.","journal-title":"Cancer Imaging"},{"issue":"4","key":"2093_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/diagnostics11040605","volume":"11","author":"A Weich","year":"2021","unstructured":"Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, et al. CXCR4-Directed PET\/CT in patients with newly diagnosed neuroendocrine carcinomas. Diagnostics. 2021;11(4):605.","journal-title":"Diagnostics"},{"issue":"2","key":"2093_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","volume":"49","author":"SM Jacobs","year":"2022","unstructured":"Jacobs SM, Wesseling P, De Keizer B, Tolboom N, Ververs FFT, Krijger GC, et al. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor \/[177Lu]Lu-Pentixather. Eur J Nucl Med Mol Imaging. 2022;49(2):481\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2093_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2967\/jnmt.122.264141","volume":"50","author":"A Watts","year":"2022","unstructured":"Watts A, Singh B, Singh H, Kaur H, Bal A, Vohra M, et al. 68 Ga-Pentixafor PET\/CT demonstrating in vivo CXCR4 receptor overexpression in rare lung malignancies: correlation with histologic and histochemical findings. J Nucl Med Technol. 2022;50(3):278\u201381.","journal-title":"J Nucl Med Technol"},{"issue":"4","key":"2093_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11307-022-01717-1","volume":"24","author":"SE Serfling","year":"2022","unstructured":"Serfling SE, Lapa C, Dreher N, Hartrampf PE, Rowe SP, Higuchi T, et al. Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET\/CT. Mol Imaging Biol. 2022;24(4):659\u201365.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"2093_CR31","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00259-022-06059-2","volume":"50","author":"A Watts","year":"2023","unstructured":"Watts A, Singh B, Singh H, Bal A, Kaur H, Dhanota N, et al. [68Ga]Ga-Pentixafor PET\/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors\u2019 density by immunochemistry techniques. Eur J Nucl Med Mol Imaging. 2023;50(4):1216\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2093_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MNM.0000000000001719","volume":"44","author":"SA Mirshahvalad","year":"2023","unstructured":"Mirshahvalad SA, Manafi-Farid R, Fallahi B, Seifi S, Geramifar P, Emami-Ardekani A, et al. Diagnostic value of [68Ga]Ga-Pentixafor versus [18F]FDG PET\/CTs in non-small cell lung cancer: a head-to-head comparative study. Nucl Med Commun. 2023;44(9):803\u20139.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"2093_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/RLU.0000000000004629","volume":"48","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, Kosmala A, Serfling SE, Bundschuh L, Higuchi T, Lapa C, et al. Interobserver agreement rates on C-X-C Motif Chemokine Receptor 4\u2013directed molecular imaging and therapy. Clin Nucl Med. 2023;48(6):483\u20138.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"2093_CR34","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2967\/jnumed.123.265464","volume":"64","author":"I Hartlapp","year":"2023","unstructured":"Hartlapp I, Hartrampf PE, Serfling SE, Wild V, Weich A, Rasche L, et al. CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors. J Nucl Med. 2023;64(9):1424\u201330.","journal-title":"J Nucl Med"},{"issue":"4","key":"2093_CR35","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/RLU.0000000000005073","volume":"49","author":"A Waheed","year":"2024","unstructured":"Waheed A, Singh B, Watts A, Kaur H, Singh H, Dhingra K, et al. 68Ga-Pentixafor PET\/CT for in vivo imaging of CXCR4 receptors in glioma demonstrating a potential for response assessment to radiochemotherapy: preliminary results. Clin Nucl Med. 2024;49(4):e141\u20138.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2093_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11307-024-01913-1","volume":"26","author":"M Liu","year":"2024","unstructured":"Liu M, Chen X, Ding H, Shu Q, Zheng Y, Chen Y, et al. Comparison of [18F]FDG and [68 Ga]pentixafor PET\/CT in nasopharyngeal carcinoma. Mol Imaging Biol. 2024;26(4):658\u201367.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"2093_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MNM.0000000000001806","volume":"45","author":"R Manafi-Farid","year":"2024","unstructured":"Manafi-Farid R, Mahini M, Mirshahvalad SA, Fallahi B, Fard-Esfahani A, Emami-Ardekani A, et al. Diagnostic value of [68Ga]Ga-Pentixafor PET\/CT in malignant melanoma: a pilot study. Nucl Med Commun. 2024;45(3):221\u20138.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"2093_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/MNM.0000000000001803","volume":"45","author":"SR Jena","year":"2024","unstructured":"Jena SR, Watts A, Aggarwal P, Bachhal V, Kaur H, Dhingra K, et al. 68Ga-Pentixafor PET\/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results. Nucl Med Commun. 2024;45(3):229\u201335.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"2093_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","volume":"51","author":"N Dreher","year":"2024","unstructured":"Dreher N, Hahner S, Fu\u00df CT, Schl\u00f6telburg W, Hartrampf PE, Serfling SE, et al. CXCR4-directed PET\/CT with [68 Ga]Ga-pentixafor in solid tumors\u2014a comprehensive analysis of imaging findings and comparison with histopathology. Eur J Nucl Med Mol Imaging. 2024;51(5):1383\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2093_CR40","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/j.clon.2024.04.011","volume":"36","author":"R Madan","year":"2024","unstructured":"Madan R, Kumar N, Dracham CB, Kumar R, Trivedi G, Tripathi M, et al. Prospective phase II study of radiotherapy dose escalation in grade 4 glioma using 68Ga-Pentixafor PET scan. Clin Oncol. 2024;36(9):e294-300.","journal-title":"Clin Oncol"},{"issue":"13","key":"2093_CR41","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/diagnostics14131375","volume":"14","author":"B Hadebe","year":"2024","unstructured":"Hadebe B, Harry L, Gabela L, Masikane S, Patel M, Zwane S, et al. Chemokine receptor-4 targeted PET\/CT imaging with 68Ga-Pentixafor in head and neck cancer\u2014a comparison with 18F-FDG and CXCR4 immunohistochemistry. Diagnostics. 2024;14(13):1375.","journal-title":"Diagnostics"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02093-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:59:52Z","timestamp":1758373192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02093-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02093-w","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This is a systematic review of published literature and does not involve any new studies with human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}